ANI Pharmaceuticals (ANIP) to Release Earnings on Friday

ANI Pharmaceuticals (NASDAQ:ANIP) will likely be posting its Q3 2025 results before the market opens on Friday, November 7th. Analysts expect ANI Pharmaceuticals to post earnings of $1.74 per share and revenue of $211.9170 million for the quarter. Individuals may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Friday, November 7, 2025 at 8:30 AM ET.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings data on Thursday, June 8th. The specialty pharmaceutical company reported ($0.12) EPS for the quarter. ANI Pharmaceuticals had a negative net margin of 1.37% and a positive return on equity of 25.03%. The business had revenue of $64.48 million during the quarter. On average, analysts expect ANI Pharmaceuticals to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.

ANI Pharmaceuticals Price Performance

Shares of ANIP stock opened at $91.93 on Friday. ANI Pharmaceuticals has a twelve month low of $52.50 and a twelve month high of $99.50. The stock has a market capitalization of $1.99 billion, a price-to-earnings ratio of -119.39 and a beta of 0.58. The stock has a fifty day simple moving average of $93.55 and a two-hundred day simple moving average of $76.57. The company has a current ratio of 2.54, a quick ratio of 1.96 and a debt-to-equity ratio of 1.39.

Insider Activity

In other ANI Pharmaceuticals news, SVP Krista Davis sold 1,000 shares of the stock in a transaction dated Friday, September 19th. The stock was sold at an average price of $98.04, for a total value of $98,040.00. Following the completion of the sale, the senior vice president directly owned 60,186 shares in the company, valued at approximately $5,900,635.44. This trade represents a 1.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Matthew J. Leonard sold 2,528 shares of the stock in a transaction dated Monday, August 25th. The shares were sold at an average price of $90.62, for a total value of $229,087.36. Following the completion of the sale, the director owned 6,864 shares of the company’s stock, valued at approximately $622,015.68. This trade represents a 26.92% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 413,830 shares of company stock worth $36,505,378 over the last ninety days. 11.10% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. Advisors Asset Management Inc. acquired a new stake in ANI Pharmaceuticals in the first quarter valued at approximately $28,000. State of Wyoming purchased a new position in ANI Pharmaceuticals during the second quarter worth approximately $50,000. Tower Research Capital LLC TRC increased its stake in ANI Pharmaceuticals by 542.0% during the second quarter. Tower Research Capital LLC TRC now owns 1,727 shares of the specialty pharmaceutical company’s stock worth $113,000 after acquiring an additional 1,458 shares during the last quarter. State of Tennessee Department of Treasury increased its stake in ANI Pharmaceuticals by 54.5% during the second quarter. State of Tennessee Department of Treasury now owns 5,762 shares of the specialty pharmaceutical company’s stock worth $376,000 after acquiring an additional 2,032 shares during the last quarter. Finally, Canada Pension Plan Investment Board increased its stake in ANI Pharmaceuticals by 90.0% during the second quarter. Canada Pension Plan Investment Board now owns 7,600 shares of the specialty pharmaceutical company’s stock worth $496,000 after acquiring an additional 3,600 shares during the last quarter. 76.05% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the company. Zacks Research upgraded ANI Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Thursday, August 21st. Guggenheim upped their target price on ANI Pharmaceuticals from $86.00 to $114.00 and gave the stock a “buy” rating in a report on Monday, September 8th. Piper Sandler reiterated an “overweight” rating and issued a $94.00 target price on shares of ANI Pharmaceuticals in a report on Friday, August 8th. Wall Street Zen upgraded ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 16th. Finally, JPMorgan Chase & Co. upped their target price on ANI Pharmaceuticals from $95.00 to $115.00 and gave the stock an “overweight” rating in a report on Wednesday, September 24th. Two equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $99.14.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.